ArticleTrials2026
Empagliflozin in improving exercise tolerance in HFpEF: study protocol for an open-label, randomized controlled study.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionHeart failure with preserved ejection fraction (HFpEF) constitutes nearly half of patients with heart failure, but there is still a lack of treatment options to improve prognosis. Empagliflozin is a new hypoglycemic medication classified as sodium glucose cotransporter 2 inhibitors (SGLT2i); nonetheless, its effects on exercise tolerance in HFpEF remain ambiguous. Additional clinical studies are necessary to clarify the effect of SGLT2i in HFpEF. This study aims to evaluate the efficacy and safety of empagliflozin on exercise tolerance in patients with heart failure with preserved ejection fraction without diabetes, using cardiopulmonary exercise testing. METHODS AND ANALYSIS: This study is a single-center, open-label, randomized controlled trial. We will randomly (1:1) assign 86 patients with an ejection fraction of more than 40% and class II-III heart failure to receive empagliflozin (10 mg once daily) or to maintain their original treatment regimen. The treatment duration will be 12 weeks. The primary endpoint is the evaluation of changes in peak oxygen uptake (peak VO2) after a 12-week period using cardiopulmonary exercise testing (CPET). The secondary endpoints encompassed additional parameters of CPET and echocardiography, N-terminal pro-B-type natriuretic peptide level, alanine aminotransferase level, aspartate transaminase level, estimated glomerular filtration rate level, New York Heart Association functional classification, and scores from the Minnesota Living with Heart Failure Questionnaire. Safety events associated with empagliflozin and CPET will be monitored. DISCUSSION: We used peak oxygen uptake, the gold standard for assessing exercise tolerance, to evaluate the efficacy and safety of empagliflozin in treating non-diabetic patients with HFpEF. The improvement in quality of life of heart failure patients by SGLT2i will be objectively assessed.
trial registrationwww.chictr.org.cn (ChiCTR2300072908). Registered on 04 July 2023.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.